SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription

Abstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-...

Full description

Bibliographic Details
Main Authors: Abdulaziz Almuqrin, Andrew D. Davidson, Maia Kavanagh Williamson, Philip A. Lewis, Kate J. Heesom, Susan Morris, Sarah C. Gilbert, David A. Matthews
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Genome Medicine
Online Access:https://doi.org/10.1186/s13073-021-00859-1
id doaj-e1230c43536748bfa473cef2663111c6
record_format Article
spelling doaj-e1230c43536748bfa473cef2663111c62021-03-21T12:11:32ZengBMCGenome Medicine1756-994X2021-03-0113111710.1186/s13073-021-00859-1SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcriptionAbdulaziz Almuqrin0Andrew D. Davidson1Maia Kavanagh Williamson2Philip A. Lewis3Kate J. Heesom4Susan Morris5Sarah C. Gilbert6David A. Matthews7School of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolProteomics Facility, Faculty of Life Sciences, University Walk, University of BristolJenner Institute, Nuffield Department of Medicine, University of OxfordJenner Institute, Nuffield Department of Medicine, University of OxfordSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolAbstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene. Methods We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. In addition, we used quantitative proteomics to study over time the proteome and phosphoproteome of A549 and MRC5 cells infected with the ChAdOx1 nCoV-19 vaccine. Results The expected SARS-CoV-2 S coding transcript dominated in all cell lines. We also detected rare S transcripts with aberrant splice patterns or polyadenylation site usage. Adenovirus vector transcripts were almost absent in MRC-5 cells, but in A549 cells, there was a broader repertoire of adenoviral gene expression at very low levels. Proteomically, in addition to S glycoprotein, we detected multiple adenovirus proteins in A549 cells compared to just one in MRC5 cells. Conclusions Overall, the ChAdOx1 nCoV-19 vaccine’s transcriptomic and proteomic repertoire in cell culture is as expected. The combined transcriptomic and proteomics approaches provide a detailed insight into the behaviour of this important class of vaccine using state-of-the-art techniques and illustrate the potential of this technique to inform future viral vaccine vector design.https://doi.org/10.1186/s13073-021-00859-1
collection DOAJ
language English
format Article
sources DOAJ
author Abdulaziz Almuqrin
Andrew D. Davidson
Maia Kavanagh Williamson
Philip A. Lewis
Kate J. Heesom
Susan Morris
Sarah C. Gilbert
David A. Matthews
spellingShingle Abdulaziz Almuqrin
Andrew D. Davidson
Maia Kavanagh Williamson
Philip A. Lewis
Kate J. Heesom
Susan Morris
Sarah C. Gilbert
David A. Matthews
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
Genome Medicine
author_facet Abdulaziz Almuqrin
Andrew D. Davidson
Maia Kavanagh Williamson
Philip A. Lewis
Kate J. Heesom
Susan Morris
Sarah C. Gilbert
David A. Matthews
author_sort Abdulaziz Almuqrin
title SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
title_short SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
title_full SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
title_fullStr SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
title_full_unstemmed SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
title_sort sars-cov-2 vaccine chadox1 ncov-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of sars-cov-2 s glycoprotein gene transcription
publisher BMC
series Genome Medicine
issn 1756-994X
publishDate 2021-03-01
description Abstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene. Methods We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. In addition, we used quantitative proteomics to study over time the proteome and phosphoproteome of A549 and MRC5 cells infected with the ChAdOx1 nCoV-19 vaccine. Results The expected SARS-CoV-2 S coding transcript dominated in all cell lines. We also detected rare S transcripts with aberrant splice patterns or polyadenylation site usage. Adenovirus vector transcripts were almost absent in MRC-5 cells, but in A549 cells, there was a broader repertoire of adenoviral gene expression at very low levels. Proteomically, in addition to S glycoprotein, we detected multiple adenovirus proteins in A549 cells compared to just one in MRC5 cells. Conclusions Overall, the ChAdOx1 nCoV-19 vaccine’s transcriptomic and proteomic repertoire in cell culture is as expected. The combined transcriptomic and proteomics approaches provide a detailed insight into the behaviour of this important class of vaccine using state-of-the-art techniques and illustrate the potential of this technique to inform future viral vaccine vector design.
url https://doi.org/10.1186/s13073-021-00859-1
work_keys_str_mv AT abdulazizalmuqrin sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT andrewddavidson sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT maiakavanaghwilliamson sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT philipalewis sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT katejheesom sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT susanmorris sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT sarahcgilbert sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
AT davidamatthews sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription
_version_ 1724210844556853248